Sonoma Biotherapeutics is inventing the future of living therapies for autoimmune disease — safe, effective treatments as unique as each individual patient. Regulatory T cell therapies that harness a patient’s own immune cells, powerful next generation gene editing techniques and advanced manufacturing and quality assurance processes. Sonoma’s mission is to create a best-in-class regulatory T cell therapy that delivers long-lasting, highly efficacious treatments leading to cures across a spectrum of autoimmune and degenerative diseases.
Location: United States, California, South San Francisco
Employees: 51-200
Total raised: $420M
Founded date: 2019
Investors 7
| Date | Name | Website |
| - | LAV | lavfund.co... |
| - | T1D Fund | t1dfund.or... |
| - | Octagon Ca... | octagoninv... |
| - | 8VC | 8vc.com |
| - | Timefolio ... | timefolioc... |
| 15.10.2020 | Lifeforce ... | lifeforcec... |
| 07.08.2021 | GV | gv.com |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 04.09.2024 | - | $45M | - |
| 04.08.2021 | Series B | $265M | - |
| 30.09.2020 | Series A | $70M | - |
| 06.02.2020 | Series A | $40M | - |
Mentions in press and media 18
| Date | Title | Description |
| 19.02.2026 | Vie Ventures Names Jeff Bluestone, PhD, As Managing Director | Vie Ventures, a life sciences venture capital firm focused on autoimmune and immune-mediated diseases, announced that Jeff Bluestone, PhD, has been named Managing Director. He joins founders Steven St. Peter, MD, and Luke Evnin, PhD, who al... |
| 03.06.2025 | Dimension Bio Appoints Biotech Veteran Heidi Hagen to Board of Directors | Heidi Hagen Dimension Bio appoints biotechnology veteran Heidi Hagen to its Board of Directors, bringing decades of cell therapy leadership as the company advances its liver failure program toward the clinic. CHICAGO, June 3, 2025 /PRNewswi... |
| 04.09.2024 | The Rise of Biotech and AgTech: A New Era of Innovation | In the heart of Silicon Valley and beyond, two companies are redefining the landscape of biotechnology and agricultural technology. Sonoma Biotherapeutics and CeresAI are not just players in their fields; they are pioneers. Their recent fun... |
| 04.09.2024 | Sonoma Biotherapeutics Receives $45M Investment From Regeneron Pharmaceuticals | Sonoma Biotherapeutics, a San Francisco, CA- and Seattle, WA-based clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, received a $45M investment from Regen... |
| 11.04.2023 | Tech Moves: Adaptive Biotechnologies COO departing; Sana adds leaders; and more | Mark Adams. (Adaptive Photo) — Mark Adams is stepping down as chief operating officer of Adaptive Biotechnologies, the company said today in a regulatory filing. Adams joined the Seattle-based biotech giant more than three years ago. The fi... |
| 28.03.2023 | Sonoma Bio inks $75M deal with Regeneron to advance cell therapies against autoimmunity | Sonoma’s therapies harness regulatory T cells (Tregs), shown here in red interacting with another type of immune cell, in blue. (National Institute of Allergy and Infectious Diseases/NIH Photo) The news: Sonoma Biotherapeutics is partnering... |
| 04.08.2021 | Why the IPO markets aren’t quite the dotcom bubble all over again | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. The now common phrase, that the pandemic has “accelerated digital trends,” has more recently been... |
| 04.08.2021 | Why the IPO markets aren’t quite the dotcom bubble all over again | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Paid Content Change your marketer experience and unleash growth for your business From Optimizely... |
| 04.08.2021 | Sonoma Biotherapeutics : Raises $265 Million in an Oversubscribed Series B Financing to Translate the Promise of Cell Therapy into Curative Medicines for Autoimmune and Other Inflammatory Diseases | Sonoma Biotherapeutics, an immune tolerance company focused on the development of regulatory T cell (Treg) therapies, has announced an oversubscribed $265 million Series B financing. Proceeds from the financing will be used to advance Sonom... |
| 04.08.2021 | Ally Bridge Portfolio News – Sonoma Biotherapeutics Raises $265 Million in an Oversubscribed Series B Financing to Translate the Promise of Cell Therapy into Curative Medicines for Autoimmune and Othe... | Sonoma Biotherapeutics’ platform and product candidates aim to restore immune system balance through complementary regulatory T cell (Treg) therapy and effector T cell (Teff) conditioning Series B financing comprised of strong syndicate of... |
Show more